- Published at
- by rttnews.com
mixed
mixed
MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301
Today's Daily Dose brings you news about the FDA lifting the partial clinical hold on Marker Therapeutics' phase II post-transplant acute myeloid leukemia trial; Rhythm selling its Rare Pediatric Disease Priority Review Voucher for $100 million; Hoth Therapeutics' financing agreement; Millendo discontinuing further development of MLE-301 for the treatment of menopausal vasomotor symptoms.